Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2013

View Archived Issues

Novel macrocycles for diabetes discovered at Harvard College

New anti-ICAM-1 MAbs developed in Korea

FAK inhibitors described at Merck & Co.

Roche issues overview of 2012 activities

AbbVie provides overview of 2012, looks ahead to 2013

VG Life Sciences reports results from sorafenib combination trial

Vitamin D deficiency linked to sepsis risk and outcomes

Hypertension treatment nebivolol investigated in Alzheimer's disease model

Combined viral vaccines developed at Novartis

Tricyclic pim kinase inhibitors reported by the Spanish CNIO

Relaxin fusion polypeptides developed at Bayer

MAbs to CCR6 developed at Kyowa Hakko Kirin

New genetic variants identified linked to autism spectrum disorders

AC Immune to discontinue development of ACI-91

Teva Pharmaceutical terminates agreements with CureTech

Phase II study under way for Cerulean's CRLX-101 in relapsed SCLC

Merck & Co. submits BLA for grass allergy immunotherapy tablet

Novel compounds described as potential therapies for nerve agent poisoning

BTG submits Varisolve NDA

Vernalis' drug discovery collaboration with Genentech yields milestone payment

FDA approves Ravicti for urea cycle disorders

Wellcome Trust award supports phase I/II trial of Newron's sNN-0029

Health Canada grants approval to Adcetris for two lymphoma indications

Alchemia reaches original enrollment target in phase III study of HA-irinotecan

Lyxumia approved in E.U. as first once-daily prandial GLP-1 receptor agonist

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...